DE69940923D1 - Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren - Google Patents

Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren

Info

Publication number
DE69940923D1
DE69940923D1 DE69940923T DE69940923T DE69940923D1 DE 69940923 D1 DE69940923 D1 DE 69940923D1 DE 69940923 T DE69940923 T DE 69940923T DE 69940923 T DE69940923 T DE 69940923T DE 69940923 D1 DE69940923 D1 DE 69940923D1
Authority
DE
Germany
Prior art keywords
constitutatively
endogenic
activated
protein coupled
oral receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940923T
Other languages
English (en)
Inventor
Dominic P Behan
Derek T Chalmers
Chen Liaw
I-Lin Lin
Kevin Lowitz
Ruoping Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69940923D1 publication Critical patent/DE69940923D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/42Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69940923T 1998-07-31 1999-07-30 Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren Expired - Lifetime DE69940923D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9487998P 1998-07-31 1998-07-31
US10630098P 1998-10-30 1998-10-30
US11090698P 1998-12-04 1998-12-04
US12185199P 1999-02-26 1999-02-26
PCT/US1999/017425 WO2000006597A2 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Publications (1)

Publication Number Publication Date
DE69940923D1 true DE69940923D1 (de) 2009-07-09

Family

ID=27492754

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940923T Expired - Lifetime DE69940923D1 (de) 1998-07-31 1999-07-30 Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren

Country Status (13)

Country Link
EP (1) EP1095275B1 (de)
JP (1) JP2002521681A (de)
CN (1) CN1231762C (de)
AT (1) ATE432472T1 (de)
AU (1) AU751080B2 (de)
CA (1) CA2338543C (de)
DE (1) DE69940923D1 (de)
DK (1) DK1095275T3 (de)
IL (1) IL140858A0 (de)
MX (1) MXPA01001176A (de)
NO (1) NO20010509L (de)
NZ (1) NZ509429A (de)
WO (1) WO2000006597A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
CN1420929A (zh) * 2000-04-07 2003-05-28 阿瑞那制药公司 非内源性组成型活化的已知g蛋白偶联受体
WO2003078602A2 (en) * 2002-03-15 2003-09-25 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
WO2003081256A2 (en) * 2002-03-22 2003-10-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
AU2003266238A1 (en) * 2002-08-05 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
AU2003291967A1 (en) * 2002-12-20 2004-07-14 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2005095990A1 (en) * 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507518A (ja) * 1995-06-07 1999-07-06 プレーシス ファーマスーティカルズ インコーポレイテッド G蛋白質とカップルしたレセプターのアゴニスト及びアンタゴニストの機能的バイオアッセイ
AU7115896A (en) * 1995-09-20 1997-04-09 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
DK0965041T3 (da) * 1997-04-14 2009-05-25 Arena Pharm Inc Fremgangsmåde til identifikation af modulatorer af celleoverflade-membranreceptorer, som kan anvendes til behandling af sygdomme

Also Published As

Publication number Publication date
IL140858A0 (en) 2002-02-10
CN1323396A (zh) 2001-11-21
WO2000006597A2 (en) 2000-02-10
EP1095275A2 (de) 2001-05-02
AU751080B2 (en) 2002-08-08
CA2338543C (en) 2009-12-29
JP2002521681A (ja) 2002-07-16
DK1095275T3 (da) 2009-09-28
MXPA01001176A (es) 2005-07-25
WO2000006597A3 (en) 2000-05-18
WO2000006597A9 (en) 2000-07-13
EP1095275B1 (de) 2009-05-27
ATE432472T1 (de) 2009-06-15
CA2338543A1 (en) 2000-02-10
CN1231762C (zh) 2005-12-14
AU5545999A (en) 2000-02-21
NO20010509D0 (no) 2001-01-30
NO20010509L (no) 2001-03-19
NZ509429A (en) 2002-06-28

Similar Documents

Publication Publication Date Title
DK1261322T3 (da) Farmaceutiske sammensætninger omfattende en adenosinreceptoragonist eller antagonist
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
DE69728893T2 (de) N-aryl substituierte tetrahydrochinoline ligande für retinoidrezeptoren mit agonist, antagonist oder inverser agonist wirkung
MEP6208A (en) The combination of a serotonin reuptake inhibitor and a 5-ht¿2c? antagonist, inverse agonist or partial agonist
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
DE60214594D1 (de) Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar)
BRPI0410884A (pt) composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
BR0007864A (pt) Composto, e, uso de um composto
EE04141B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas
BRPI0413676A (pt) composto, e, composição farmacêutica
DE69940923D1 (de) Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
DE69941298D1 (de) Radiomarkierte neurokinin-1 rezeptor antagonisten
BR0318631A (pt) os agonistas receptores peptìdeo-1 similares ao glucagon, a preparação e o uso do mesmo
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
DE69703242T2 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
BR0010882A (pt) Agonistas receptores de adenosina a1 oralmente ativos e processo para uso de tal composição
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
DE69903716D1 (de) Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten
PT1042320E (pt) Novos compostos que sao antagonistas de receptores duplos de ourinoceptores p2 e de proteina g 7-transmembranar
NO20035771L (no) Assays for EPF-reseptorforbindelser samt terapeutiske sammensetninger
PT1068198E (pt) Indoles 5-heteroarilo substituidos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition